Results 241 to 250 of about 131,925 (308)

Clinicopathological and molecular heterogeneity of amyloid‐β in unnatural deaths under 70 years: A forensic autopsy–based study

open access: yesBrain Pathology, EarlyView.
This study investigates amyloid‐beta (Aβ) pathology in a forensic autopsy cohort of relatively young individuals (40–69 years). Using detailed immunohistochemical analyses of multiple Aβ species, we demonstrate marked regional and molecular heterogeneity, particularly within the striatum.
Shojiro Ichimata   +4 more
wiley   +1 more source

Toward personalized medicine in AD/ADRD through genetic-exposome dementia risk assessments. [PDF]

open access: yesNPJ Dement
Tolosa-Tort P   +5 more
europepmc   +1 more source

Factors associated with intracerebral hemorrhage in confirmed cerebral amyloid angiopathy. [PDF]

open access: yesAlzheimers Dement
Chaachou-Charradi A   +8 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

<i>APOE</i> ε4, physical activity, and the brain: a review of systematic reviews. [PDF]

open access: yesFront Aging Neurosci
Ali N   +7 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy